I am a scientific leader with more than 30 years’ experience in treating patients with chronic conditions. The opportunity to innovate and push boundaries that can lead to life changing discoveries is what drives me every day. It’s been a fantastic journey so far. I’m constantly being challenged and surprised, and I learn new things every day.
After training as an endocrinologist, I worked for 15 years in clinical practice and diabetes research at Uppsala University Hospital, in Sweden. I loved meeting so many different people and helping them live full lives in spite of their diabetes – and that still inspires my work today.
When I was asked in 2002 to come to work for AstraZeneca, it was the opportunity of a lifetime to develop groundbreaking medicines.
When I was asked in 2002 to come to work for AstraZeneca, it was the opportunity of a lifetime to develop groundbreaking medicines. My work shifted from treating patients individually to being able to help millions of people.
In my current role, I am in charge of development strategy and delivery across AstraZeneca’s cardiovascular, renal and metabolism (CVRM) portfolio, which includes building up the entire franchises for each of these areas. I encourage my team to use new approaches to better understand the science behind the medicines. We are developing ways of treatment that are holistic – we are focused on treating the whole patient and addressing underlying risks.
We are at the forefront of science and constantly encourage people to do things they didn’t think were possible.
Developing a greater understanding of what patients really need, and how our medicines can help them in this context, has been extremely rewarding. It has also enabled us to advance and bring together the CVRM franchises. I am really proud of the work my team is doing.
I am passionate about innovation and enjoy pushing boundaries to make breakthroughs that can change lives.
I led the development of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to treat patients with type-2 diabetes and secured its first-in-class approval for diabetes treatment in Europe. I felt able to give back to the patients I'd previously served in a whole new capacity.
In just four years, we have completely changed the culture at the Gothenburg site. We have recreated it as a BioVenture Hub by offering our office and laboratory space to biotech companies and academic groups. It is now a vibrant, inspiring, innovative, curious, collaborative environment, where people like to be and where they learn from – and challenge – each other. We are at the forefront of science and constantly encourage people to do things they didn’t think were possible. I am very proud of that.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.